No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin
Transplant International · 2025
DOI: 10.3389/ti.2024.13545 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transplant International, 2025. Verfasst von Nathalie Grall und 18 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Service de Bactériologie, Paris, France. Hauptthemen laut MEDLINE: Colistin, Lung Transplantation, Anti-Bacterial Agents, Drug Resistance, Bacterial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Secondary prophylaxis using inhaled colistin (IC) was implemented to prevent recurrences of Pseudomonas aeruginosa or extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE) pneumonia during the postoperative intensive care unit (ICU) stay after lung transplantation (LT). We evaluated the risk of emergence of colistin resistance in the respiratory tract during secondary IC prophylaxis. We conducted a prospective, single-centre, observational study of all adult patients who underwent LT between 1 July 2018 and 30 June 2019. IC was started and continued for at least 90 days for P. aeruginosa or ESBL-PE pneumonia. During the 90 days following LT, all respiratory samples were routinely tested for the presence of GNB of reduced susceptibility to colistin. Twenty-seven (38.6%) of the 70 included patients received IC. Among the 867 respiratory samples tested, IC did not promote the emergence of bacterial species with natural or acquired resistance to colistin (incidence-rate ratio of 0.21 [0.03–1.58], p = 0.13 and 1.68 [0.55–5.12], p = 0.37, respectively). Our study suggests no association between the use of IC and an increased risk of colistin resistance in the respiratory tract within 90 days of LT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Service de Bactériologie, Paris, France.
- INSERM UMR 1137 IAME, Université Paris Cité, Paris, France.
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d'Anesthésie-Réanimation, Paris, France.
- Université Paris Cité, AP-HP, Hôpital Bichat, Département d'Epidémiologie et Recherche Clinique, Paris, France.
- Réunion Island University, INSERM U1188 Diabetes Atherothrombosis Réunion Indian OCean (DéTROI), CYROI Plateform, Saint-Denis de La Réunion, France.
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Pneumologie B et Transplantation Pulmonaire, Paris, France.
Zitieren
APA
Grall, N., Assadi, M., Esposito-Farese, M., Lortat-Jacob, B., Tanaka, S., Atchade, E., Messika, J., Bunel, V., Mal, H., Mordant, P., Castier, Y., Garnier, B., Gueye, S., Petitjean, M., Denamur, E., Armand-Lefevre, L., Burdet, C., Montravers, P., & Tran-Dinh, A. (2025). No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin. Transplant International. https://doi.org/10.3389/ti.2024.13545
Vancouver
Grall N, Assadi M, Esposito-Farese M, Lortat-Jacob B, Tanaka S, Atchade E, et al. No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin. Transplant International. 2025. doi:10.3389/ti.2024.13545
BibTeX
@article{Grall2025,
author = {Grall, Nathalie and Assadi, Maksud and Esposito-Farese, Marina and Lortat-Jacob, Brice and Tanaka, Sébastien and Atchade, Enora and Messika, Jonathan and Bunel, Vincent and Mal, Hervé and Mordant, Pierre and Castier, Yves and Garnier, Bastien and Gueye, Signara and Petitjean, Marie and Denamur, Erick and Armand-Lefevre, Laurence and Burdet, Charles and Montravers, Philippe and Tran-Dinh, Alexy},
title = {No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin},
journal = {Transplant International},
year = {2025},
doi = {10.3389/ti.2024.13545}
}
EUVIMED